HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

503.398

-20.475-3.91%

Number of Gainers:8

Number of Losers:24

Number of Flat:1

PE:- -

High:523.582

Open:523.582

Low:498.297

Close:523.873

Volume:119.87M

Turnover:3.20B

Market Cap:322.68B

Float Cap:286.07B

Loading ...

RemeGen (SEHK:9995) Stock Profit Surge Meets Doubts Over Earnings Durability

Simply Wall St.

Jiangsu Unveils Plan to Encourage Inclusion of Innovative Drugs in Commercial Health Insurance and Mutual Aid Coverage

Citi Lifts REMEGEN Price Target to HK$127.7, Keeps Buy/High-Risk Call

CLSA Raises REMEGEN Price Target to HK$144.8, Reiterates Outperform Rating on Strong Q2 Beat

Delisting Doesn't Halt Claims! Investors in Poly Pharm (300630) File Another Court Case

Fosun Pharma's H1 Report: Innovative Drug Revenue Surges 13.8% as Global Expansion Spans Three Continents

HK Stock Alert | TH MEDICAL-B Surges Over 6% on Northeast China Oncology Partnership, Accelerating Commercial Momentum

Hong Kong Biotech Sector Surges Again as Innovative Drug Stocks Lead Gains, INNOVENT BIO Hits Record High

SIHUAN PHARM Posts 119% Profit Surge in Interim Results, Reinforcing Dual-Engine Strategy

Morning Market Wrap: Hong Kong Shares Rise 0.68% as Copper Stocks Take the Lead

Waterdrop's Yifan Medicine Cracks Clinical Recruitment Hurdle in Extensive-Stage Small Cell Lung Cancer, Setting a New Service Benchmark

China's Akeso Jumps on Progress of Immunotherapy Drug for Cancer Treatment

AKESO Surges Over 9% in Session as Evonex Achieves Positive Phase III Results in Biliary Tract Cancer

HK Stock Market Flash: PEIJIA-B (09996) Climbs Over 5% Again, Lifts Full-Year TAVR Volume Guidance After Strong Interim Results

HK Biotech Shares Surge as CansinoBio Jumps Over 18%

Akeso's Ivonescimab Meets Primary Endpoint in Phase 3 Biliary Tract Cancer Trial

MT Newswires Live

Akeso Says Ivonescimab Plus Chemo Meets Primary Endpoint

Finally Tasting the Gains in the Healthcare Sector Today!

HK Stock Market Highlights: Haizhi Tech's H1 FY2026 Revenue Jumps 70.4% as Agent Business Takes Off

Novartis Secures New Chinese Approval for Key Radiopharmaceutical Therapy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BK1574/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":503.39795,"timestamp":1788163726135,"preClose":523.8731,"halted":0,"volume":119868273,"delay":0,"changeRate":-0.039084,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-20.475159,"latestTime":"08-31 16:00:00","open":523.582,"high":523.582,"low":498.29733,"amount":3203299214.5,"amplitude":0.048265,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"pbRate":3.909696,"peRate":137.956161,"turnoverRate":0.003654,"increases":8,"decrements":24,"flats":1,"marketCap":322680201168,"floatMarketCap":286067329608},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":523.582,"amplitude":0.048265,"preClose":523.8731,"low":498.29733,"pbRate":"3.909696","latestPrice":503.39795,"volume":119868273,"delay":0,"open":523.582,"prevYearClose":556.26263,"prevWeekClose":523.873,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":496.742,"twentyDayClose":467.18,"sixtyDayClose":475.465,"secType":"PLATE","market":"HK","turnoverRate":0.003654,"peRate":137.956161,"marketCap":322680201168,"floatMarketCap":286067329608,"timestamp":1788163726135,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":8,"down":24,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662184712","title":"RemeGen (SEHK:9995) Stock Profit Surge Meets Doubts Over Earnings Durability","url":"https://stock-news.laohu8.com/highlight/detail?id=2662184712","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662184712?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:43","pubTimestamp":1787741007,"startTime":"0","endTime":"0","summary":"RemeGen stock closed at HK$80.40 on Wednesday, only slightly higher over the past week, even as the latest earnings landed with a jolt. The headline is simple: profitability in Q2 looks striking on paper, with basic earnings per share of ¥7.81 driven by net income of ¥4,334.28m. Yet the stock still trades on a trailing P/E of 6.6x while Hong Kong biotech peers sit far higher. The sentiment gap today relates to investors questioning how much of that earnings power is durable and how much the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-stock-profit-surge-meets-doubts-over-earnin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-stock-profit-surge-meets-doubts-over-earnin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["JOYT","LU1969619763.USD","DECU","LU2328871848.SGD","GXDW","BK1161","PMDE","VOTE","RGLO","09995","FEBU","BK1574","VGFPF","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136653718","title":"Jiangsu Unveils Plan to Encourage Inclusion of Innovative Drugs in Commercial Health Insurance and Mutual Aid Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=1136653718","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136653718?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:11","pubTimestamp":1787739064,"startTime":"0","endTime":"0","summary":"On August 26, in a financial frontline update, Jiangsu Province issued the \"Three-Year Action Plan for Promoting High-Quality Development of the Biomedical Industry.\" The plan highlights the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","159891","LNGR","BK4588","MEDX","XLV","BK4581","BK1161","XBI","159992","LABU","BK1574","BK4585","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120378751","title":"Citi Lifts REMEGEN Price Target to HK$127.7, Keeps Buy/High-Risk Call","url":"https://stock-news.laohu8.com/highlight/detail?id=1120378751","media":"Stock News","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120378751?lang=en_us&edition=fundamental","pubTime":"2026-08-26 17:16","pubTimestamp":1787735782,"startTime":"0","endTime":"0","summary":"Citi has issued a research report highlighting that REMEGEN (09995) posted a 433% year-on-year revenue surge in the first half, swinging to a profit of RMB 4.66 billion. Management noted that...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","09995","LU0162691827.USD","LU1201861249.SGD","LU0130517989.USD","LU1074936037.SGD","LU1267930227.SGD","LU0098860793.USD","TFNS","688331","LU0203347892.USD","LU2236285917.USD","LU0052756011.USD","BK4588","LU2462157665.USD","LU0314106906.USD","BK4559","LU0170899867.USD","LU0106831901.USD","LU0477156953.USD","LU1244550577.SGD","LU1064130708.USD","LU1668664300.SGD","LU2456880835.USD","LU1366192091.USD","BK4504","LU0648001328.SGD","BK4534","LU0203345920.USD","FTXO","LU0072461881.USD","LU2417539215.USD","BK4207","LU2488822045.USD","BK1574","LU1064131003.USD","LU1791807156.HKD","LU2148510915.USD","LU0310800965.SGD","IE00BSNM7G36.USD","LU2360032135.SGD","BK1161","LU2125154935.USD","LU1162221912.USD","LU2125154778.USD","LU1244550494.USD","EWH","BK0239","LU1144417596.USD","LU1506573853.SGD","LU2328871848.SGD","LU1969619763.USD","LU0320765646.SGD","LU0130102774.USD","IYF","LU0128525689.USD","LU1244550221.USD","LU0980610538.SGD","C","BK4585","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155760828","title":"CLSA Raises REMEGEN Price Target to HK$144.8, Reiterates Outperform Rating on Strong Q2 Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1155760828","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155760828?lang=en_us&edition=fundamental","pubTime":"2026-08-26 16:28","pubTimestamp":1787732904,"startTime":"0","endTime":"0","summary":"CLSA has released a research report highlighting that REMEGEN (09995) delivered a remarkable 808.6% year-on-year sales growth in the second quarter of 2026, reaching a net profit of RMB 4.334...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","EWH","LU1064130708.USD","LU1064131003.USD","BK1574","688331","LU1969619763.USD","LU2328871848.SGD","LU2148510915.USD","BK1583","LU2488822045.USD","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155077826","title":"Delisting Doesn't Halt Claims! Investors in Poly Pharm (300630) File Another Court Case","url":"https://stock-news.laohu8.com/highlight/detail?id=1155077826","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155077826?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:21","pubTimestamp":1787728863,"startTime":"0","endTime":"0","summary":"On August 21, 2026, attorney Xu Feng from Shanghai Jiucheng Law Firm, who specializes in stock claim litigation, submitted another round of case filings to the Haikou Intermediate People's Court on...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300630","01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171725498","title":"Fosun Pharma's H1 Report: Innovative Drug Revenue Surges 13.8% as Global Expansion Spans Three Continents","url":"https://stock-news.laohu8.com/highlight/detail?id=1171725498","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171725498?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:00","pubTimestamp":1787727650,"startTime":"0","endTime":"0","summary":"On August 25, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH; 02196.HK) unveiled its first-half scorecard. The interim results, disclosed on the evening of August 25, show operating...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK0188","BK0060","BK0187","BK1593","BK0183","LNGR","BK0175","IBBQ","BK0196","BK1191","06978","BK1574","BK0239","BK0028","BK1161","02196","BK0012","BK0096","159992","MEDX","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159680802","title":"HK Stock Alert | TH MEDICAL-B Surges Over 6% on Northeast China Oncology Partnership, Accelerating Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1159680802","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159680802?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:39","pubTimestamp":1787726346,"startTime":"0","endTime":"0","summary":"Shares of TH MEDICAL-B (02697) climbed more than 6% in Monday trading, last up 5.09% to HK$692 with turnover reaching HK$11.3 million.On August 25, the company issued a voluntary announcement...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159891","VXUS","BK4588","02697","KCAI","BK1161","BK1515","159938","BK1574","BK4585","BK1100","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149059268","title":"Hong Kong Biotech Sector Surges Again as Innovative Drug Stocks Lead Gains, INNOVENT BIO Hits Record High","url":"https://stock-news.laohu8.com/highlight/detail?id=1149059268","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149059268?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:02","pubTimestamp":1787724134,"startTime":"0","endTime":"0","summary":"Hong Kong healthcare stocks continued their upward momentum on August 26, with innovative drug developers taking over the leadership baton from the CXO sector. Cansino Biologics Inc. soared more than...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","BK1574","LU2488822045.USD","LU0326950275.SGD","KURE","LU2097828557.USD","LU0502904849.HKD","MEDX","LU0244354667.USD","LNGR","BK1589","LU2242644610.SGD","159992","FLHK","01801","LU2328871848.SGD","LU1188198961.HKD","LU2097828631.EUR","LU0463099449.HKD","LU2097828714.EUR","LU0455707207.USD","LU2097828474.EUR","LU1969619763.USD","688185","159646","BK0239","06978","HK0000165453.HKD","BK1583","LU2097828805.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191993997","title":"SIHUAN PHARM Posts 119% Profit Surge in Interim Results, Reinforcing Dual-Engine Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1191993997","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191993997?lang=en_us&edition=fundamental","pubTime":"2026-08-26 12:36","pubTimestamp":1787718981,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) has reported its interim results for the six months ended June 30, 2026, showcasing a substantial jump in profitability. The group recorded a total revenue of RMB 1.161 billion,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1191","BK1593","BK1574","IBBQ","BK1515","LNGR","BK1600","BK1161","159992","MEDX","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154655464","title":"Morning Market Wrap: Hong Kong Shares Rise 0.68% as Copper Stocks Take the Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=1154655464","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154655464?lang=en_us&edition=fundamental","pubTime":"2026-08-26 12:07","pubTimestamp":1787717221,"startTime":"0","endTime":"0","summary":"Hong Kong's benchmark index kicked off the morning session with a 0.68% gain, advancing 174 points to reach 25,685 points, while the tech-heavy Hang Seng Tech Index climbed a more robust 1.58%....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","LU1328277881.USD","LU1481107354.HKD","LU0540923850.HKD","LU1961090484.USD","BK1574","IE00BGHQDM52.EUR","06166","02833","03088","BK1191","BK1580","LU2039709279.SGD","LU0359201612.USD","09088","KURE","02313","LU0140636845.USD","LU1102505929.USD","SG9999004220.SGD","LU0348766576.USD","SG9999004311.SGD","688185","LU2213484517.USD","07552","IE00BVYPNP33.GBP","82800","IE00BZ08YT58.USD","07300","LU0181495838.USD","LU0417516738.SGD","LU2929501877.USD","LU0890818403.SGD","00358","03419","03115","IE0031814852.USD","LU1102505762.USD","LU2045819591.USD","LU2187417386.USD","LU0244354667.USD","600999","LU0405327494.USD","BK1190","03908","LU0149534421.HKD","LU1720050803.USD","LU2476274308.USD","BK1553","SG9999002950.SGD","BK1597","LU0348735423.USD","IE00BMCWC346.EUR","LU1813983027.USD","HK0000286598.CNH","03423","IE00BVYPNQ40.USD","IE0008368742.USD","LU0607220059.USD","SG9999002828.SGD","06831","06969","IE00B031J352.USD","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","HTImain","BK1501","IE00BPRC5H50.USD","BK1206","MCHmain","LU0359202008.SGD","LU0605514214.HKD","LU0359201885.HKD","LU0828237940.HKD","LU0348784397.USD","BK1564","LU0650527681.SGD","LU1023057109.AUD","LU0862451837.USD","BK1594","BK1589","BK1184","01828","HHImain","LU0594300419.USD","BK1240","01112","IE00B031HY20.USD","LU1048596156.SGD","LU1880383366.USD","03033","BK1592","LU0821914370.USD","LU0052750758.USD","BK1227","BK1513","LU1188198961.HKD","09926","IE00B29SXG58.USD","LU0417516571.SGD","603993","BK1233","600362","LU2778985437.USD","IE00BYV24P56.USD","603083","BK1516","LU0634319403.HKD","09067","HSImain","LU1831875114.USD","HSTECH","LU0326950275.SGD","LU0561508036.HKD","LU2476274720.SGD","BK1237","LU1794554557.SGD","LU2125910500.SGD","601995","01258","BK1242","LU0348827113.USD","LU0348783233.USD","BK1568","IE00BZ08YR35.GBP","LU0862451753.SGD","07226","BK1149","BK1147","IE00B543WZ88.USD","07500","03032","SG9999014674.SGD","03037","02575","LU2488822045.USD","LU0348767384.USD","LU0348825331.USD","LU0314109678.HKD","03993","LU0405327148.USD","BK1515","IE0008369823.USD","LU1880383440.USD","LU2351347302.SGD","LU0417516902.SGD","09115","BK1521","LU0164880469.USD","LU0463099449.HKD","LU0594300179.USD","06099","LU0708995583.HKD","BK1161","02800","HSI","02837","83115","LU0149721374.USD","LU0320764599.SGD","LU2399975544.HKD","03067","513600","03417","07200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177433419","title":"Waterdrop's Yifan Medicine Cracks Clinical Recruitment Hurdle in Extensive-Stage Small Cell Lung Cancer, Setting a New Service Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=1177433419","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177433419?lang=en_us&edition=fundamental","pubTime":"2026-08-26 11:42","pubTimestamp":1787715763,"startTime":"0","endTime":"0","summary":"Waterdrop Inc. (NYSE: WDH) has announced a major breakthrough through its Yifan Medicine division, a professional clinical research recruitment service provider. The division recently completed a...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4173","BK4509","BK1515","BK1161","09939","159938","BK4539","BK1574","WDH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662769060","title":"China's Akeso Jumps on Progress of Immunotherapy Drug for Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662769060","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662769060?lang=en_us&edition=fundamental","pubTime":"2026-08-26 10:33","pubTimestamp":1787711596,"startTime":"0","endTime":"0","summary":"BUZZ-China's Akeso jumps on progress of immunotherapy drug for cancer treatment** Shares of China-based drug developer Akeso Inc9926.HKjump 9% to HK$96.9, on track for the biggest one-day pct gain since June 29** Stock hits the highest level since August 20 in the second gaining session** Akeso saysivonescimab plus chemomeets primary endpoint with significant overall survival benefit versus durvalumab plus chemo in phase III clinical study for the first-line treatment of advanced biliary tract cancer** The study met all key secondary endpoints of progression-free survival and objective response rate - Co** YTD, stock down 14.8%, while Hang Seng Biotech Index.HSBIOup 15.7%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N025:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","LU2488822045.USD","IE00B5MMRT66.SGD","LU2476274308.USD","LU0634319403.HKD","LU0417516571.SGD","LU0561508036.HKD","LU0417516738.SGD","LU2476274720.SGD","LU0348783233.USD","KURE","LU0348825331.USD","LU1720050803.USD","BK1161","LU0348784397.USD","LU2778985437.USD","09926","LU1794554557.SGD","LU0348735423.USD","LU0348766576.USD","IE00BPRC5H50.USD","LU2399975544.HKD","LU0348827113.USD","IE00B543WZ88.USD","LU1961090484.USD","LU0348767384.USD","BK1574","LU0540923850.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147226125","title":"AKESO Surges Over 9% in Session as Evonex Achieves Positive Phase III Results in Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1147226125","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147226125?lang=en_us&edition=fundamental","pubTime":"2026-08-26 10:31","pubTimestamp":1787711462,"startTime":"0","endTime":"0","summary":"Shares of AKESO (09926) surged more than 9% during intraday trading before paring gains to trade 6.81% higher at HK$94.85, with turnover reaching HK$814 million. The sharp move followed the company's...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","BK1161","LU0540923850.HKD","LU0417516902.SGD","BK4134","LU0417516571.SGD","LU0348784397.USD","LU2488822045.USD","LU0348783233.USD","LU0561508036.HKD","LU0348766576.USD","LU1961090484.USD","LU0348825331.USD","LU2476274720.SGD","LU0348827113.USD","III","LU1794554557.SGD","LU1720050803.USD","09926","LU0348767384.USD","LU0348735423.USD","LU0634319403.HKD","LU2778985437.USD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU2476274308.USD","IE00B543WZ88.USD","KURE","BK1574","LU2399975544.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160004309","title":"HK Stock Market Flash: PEIJIA-B (09996) Climbs Over 5% Again, Lifts Full-Year TAVR Volume Guidance After Strong Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1160004309","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160004309?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:54","pubTimestamp":1787709256,"startTime":"0","endTime":"0","summary":"Shares of PEIJIA-B (09996) extended their rally, climbing more than 5% during Monday's trading session. At the time of writing, the stock was up 3.14% at HK$5.58, with turnover reaching HK$1.25...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","VXUS","159891","BK4585","BK1100","KCAI","BK1583","BK4588","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176024527","title":"HK Biotech Shares Surge as CansinoBio Jumps Over 18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176024527","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176024527?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:50","pubTimestamp":1787709027,"startTime":"0","endTime":"0","summary":"Shares of Hong Kong-listed biopharmaceutical companies continued their recent rally on Tuesday, with CANSINOBIO surging 18%, 信达生物 climbing over 11% following its earnings release, 云顶新耀 rising more...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","06185","KCAI","161726","BK1574","BK4588","BK1515","BK1191","BK4585","VXUS","BK1161","399441","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662766269","title":"Akeso's Ivonescimab Meets Primary Endpoint in Phase 3 Biliary Tract Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766269","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662766269?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:41","pubTimestamp":1787708502,"startTime":"0","endTime":"0","summary":"Akeso  said its PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy met the primary endpoint in a Phase 3 trial for first-line treatment of advanced biliary tract cancer.The trial met its primary endpoint of overall survival, with key secondary endpoints of progression-free survival and objective response rate also met, according to a Wednesday filing with the Hong Kong bourse.The HARMONi-GI1 study enrolled 682 patients, marking ivonescimab's first positive Phase 3 result in gastrointestinal tumors, Akeso said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1794554557.SGD","KURE","LU0417516738.SGD","LU0348784397.USD","IE00BPRC5H50.USD","LU0348735423.USD","LU0348766576.USD","IE00B5MMRT66.SGD","LU2488822045.USD","LU0348827113.USD","LU2778985437.USD","LU1720050803.USD","LU0348783233.USD","LU0417516902.SGD","LU0561508036.HKD","LU0348825331.USD","LU0348767384.USD","LU2476274720.SGD","09926","IE00B543WZ88.USD","LU1961090484.USD","LU0634319403.HKD","LU2476274308.USD","LU0540923850.HKD","LU2399975544.HKD","BK1161","LU0417516571.SGD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662766696","title":"Akeso Says Ivonescimab Plus Chemo Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766696","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662766696?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:29","pubTimestamp":1787707747,"startTime":"0","endTime":"0","summary":"BRIEF-Akeso Says Ivonescimab Plus Chemo Meets Primary EndpointAug 26 (Reuters)-Akeso Inc9926.HK:IVONESCIMAB PLUS CHEMO MEETS PRIMARY ENDPOINT WITH SIGNIFICANT OS BENEFIT IN 1L BTCFurther company coverage:9926.HK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44M0TW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","LU2778985437.USD","BK1161","BK1574","LU2476274308.USD","LU0417516738.SGD","LU1961090484.USD","LU0540923850.HKD","LU0417516902.SGD","LU0348784397.USD","LU0417516571.SGD","LU0348825331.USD","LU0561508036.HKD","LU0348767384.USD","IE00B5MMRT66.SGD","KURE","09926","LU0348783233.USD","LU0348735423.USD","LU2488822045.USD","LU2399975544.HKD","IE00BPRC5H50.USD","LU0634319403.HKD","LU0348827113.USD","LU0348766576.USD","LU1720050803.USD","LU2476274720.SGD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192662003","title":"Finally Tasting the Gains in the Healthcare Sector Today!","url":"https://stock-news.laohu8.com/highlight/detail?id=1192662003","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192662003?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:21","pubTimestamp":1787707280,"startTime":"0","endTime":"0","summary":"After Bessent detailed the \"economic war\" tactics against Iran, oil prices took a sharp dive. This isn't because the conflict has reached its conclusion; rather, the US Treasury is expanding the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","159938","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115078027","title":"HK Stock Market Highlights: Haizhi Tech's H1 FY2026 Revenue Jumps 70.4% as Agent Business Takes Off","url":"https://stock-news.laohu8.com/highlight/detail?id=1115078027","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115078027?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:17","pubTimestamp":1787707028,"startTime":"0","endTime":"0","summary":"Key corporate developments this week: GenFleet Therapeutics-B (02595) has initiated a Phase II study evaluating GFH375, an oral KRAS G12D inhibitor, as a first-line treatment for non-small cell lung...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","00660","BK4585","BK1589","LU1961090484.USD","LU0417516902.SGD","BK1586","LU2488822045.USD","LU0348827113.USD","KCAI","BK4588","BK1574","00354","IE00B543WZ88.USD","VXUS","BK1526","LU0417516571.SGD","LU0561508036.HKD","IE00B5MMRT66.SGD","LU2778985437.USD","LU0348825331.USD","LU2476274308.USD","LU0417516738.SGD","BK1518","LU1794554557.SGD","BK1161","BK1237","LU1720050803.USD","02595","LU0348783233.USD","LU2399975544.HKD","LU0634319403.HKD","LU2476274720.SGD","LU0348766576.USD","LU0348735423.USD","LU0540923850.HKD","09926","LU0348784397.USD","BK1155","KURE","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129968594","title":"Novartis Secures New Chinese Approval for Key Radiopharmaceutical Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1129968594","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129968594?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:50","pubTimestamp":1787705420,"startTime":"0","endTime":"0","summary":"On August 25, Novartis AG (NVS.US) announced that its radiopharmaceutical lutetium [177Lu] vipivotide tetraxetan (Chinese brand name: Paiweitou) received a new indication approval in China. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS","IE00BJT1NW94.SGD","LU0070302665.USD","BK4532","BK1574","IE00B4R5TH58.HKD","01477","IE0002141913.USD","IE00B2B36J28.USD","LU0211331839.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","IE00BJJMRZ35.SGD","MEDX","BK4578","IE0009355771.USD","LU0208291251.USD","BK1191","BK4588","PPH","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":19,"pageCount":8,"totalSize":380,"code":"91000000","status":"200"}]}}